If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced ...

Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC. Read why I'm bearish on ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's ...